154 related articles for article (PubMed ID: 38271661)
1. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis.
El Otmani H; Frunt R; Smits S; Barendrecht AD; de Maat S; Fijnheer R; Lenting PJ; Tersteeg C
Blood; 2024 May; 143(20):2089-2098. PubMed ID: 38271661
[TBL] [Abstract][Full Text] [Related]
2. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
3. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.
de Maat S; Clark CC; Barendrecht AD; Smits S; van Kleef ND; El Otmani H; Waning M; van Moorsel M; Szardenings M; Delaroque N; Vercruysse K; Urbanus RT; Sebastian S; Lenting PJ; Hagemeyer CE; Renné T; Vanhoorelbeke K; Tersteeg C; Maas C
Blood; 2022 Jan; 139(4):597-607. PubMed ID: 34752601
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
5. Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
Tersteeg C; Joly BS; Gils A; Lijnen R; Deckmyn H; Declerck PJ; Plaimauer B; Coppo P; Veyradier A; Maas C; De Meyer SF; Vanhoorelbeke K
J Thromb Haemost; 2017 Dec; 15(12):2432-2442. PubMed ID: 28981198
[TBL] [Abstract][Full Text] [Related]
6. Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Shin Y; Miyake H; Togashi K; Hiratsuka R; Endou-Ohnishi K; Imamura Y
J Biochem; 2018 May; 163(5):381-389. PubMed ID: 29228282
[TBL] [Abstract][Full Text] [Related]
7. Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura.
Adili R; Holinstat M
Arterioscler Thromb Vasc Biol; 2019 Sep; 39(9):1817-1830. PubMed ID: 31340669
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.
Feys HB; Vandeputte N; Palla R; Peyvandi F; Peerlinck K; Deckmyn H; Lijnen HR; Vanhoorelbeke K
J Thromb Haemost; 2010 Sep; 8(9):2053-62. PubMed ID: 20553378
[TBL] [Abstract][Full Text] [Related]
9. Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.
Joly BS; Darmon M; Dekimpe C; Dupont T; Dumas G; Yvin E; Beranger N; Vanhoorelbeke K; Azoulay E; Veyradier A
J Thromb Haemost; 2021 Sep; 19(9):2193-2198. PubMed ID: 34219357
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of thrombotic thrombocytopenic purpura.
Tsai HM
Int J Hematol; 2010 Jan; 91(1):1-19. PubMed ID: 20058209
[TBL] [Abstract][Full Text] [Related]
11. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
[TBL] [Abstract][Full Text] [Related]
12. A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura.
Hoirisch-Clapauch S; Nardi AE
Med Hypotheses; 2014 Dec; 83(6):747-50. PubMed ID: 25459148
[TBL] [Abstract][Full Text] [Related]
13. Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome.
Habe K; Wada H; Matsumoto T; Ohishi K; Ikejiri M; Tsuda K; Kondo M; Kamimoto Y; Ikeda T; Katayama N; Mizutani H
Clin Appl Thromb Hemost; 2017 Sep; 23(6):622-630. PubMed ID: 26759371
[TBL] [Abstract][Full Text] [Related]
14. ADAMTS13 and TTP.
Zheng X; Majerus EM; Sadler JE
Curr Opin Hematol; 2002 Sep; 9(5):389-94. PubMed ID: 12172456
[TBL] [Abstract][Full Text] [Related]
15. Identification of ADAMTS13 Inhibitors in Acquired TTP.
Favaloro EJ; Chapman K; Mohammed S; Vong R; Pasalic L
Methods Mol Biol; 2023; 2663():505-521. PubMed ID: 37204733
[TBL] [Abstract][Full Text] [Related]
16. [anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura].
Matsumoto M
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(2):95-103. PubMed ID: 23629429
[TBL] [Abstract][Full Text] [Related]
17. Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP.
Pillai VG; Bao J; Zander CB; McDaniel JK; Chetty PS; Seeholzer SH; Bdeir K; Cines DB; Zheng XL
Blood; 2016 Jul; 128(1):110-9. PubMed ID: 27207796
[TBL] [Abstract][Full Text] [Related]
18. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis.
Chauhan AK; Walsh MT; Zhu G; Ginsburg D; Wagner DD; Motto DG
Blood; 2008 Apr; 111(7):3452-7. PubMed ID: 18083848
[TBL] [Abstract][Full Text] [Related]
19. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission.
Groot E; Fijnheer R; Sebastian SA; de Groot PG; Lenting PJ
J Thromb Haemost; 2009 Jun; 7(6):962-9. PubMed ID: 19548905
[TBL] [Abstract][Full Text] [Related]
20. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
Furlan M; Lämmle B
Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
